Allied Market Research


Cardiovascular Drug Market

Cardiovascular Drug Market Size, Share, Competitive Landscape and Trend Analysis Report by Drug Type, by Disease Indication and by Distribution Channels : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Cardiovascular drug market Outlook - 2030

Cardiovascular drugs refers to prescription drugs and medicines for diseases relating to the structure and function of the heart and blood vessels and diseases such as heart failure, coronary artery disease, high cholesterol, blood clots, circulation disorders, and others. These diseases are associated with circulatory system and heart. The cardiovascular diseases such as rheumatic heart disease, hypertensive heart disease, inflammatory heart disease, ischemic heart disease, and cerebrovascular heart disease. High blood pressure causes hypertensive heart disease. Key concerns related to hypertensive heart disease are hypertrophy, heart failure, angina, and coronary heart disease. Brain blood vessels get affected by the cerebrovascular disease. Cerebrovascular disease common types are a stroke, vascular dementia, transient ischemic attack, and subarachnoid haemorrhage.

Covid-19 Scenario analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the cardiovascular drug market.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact analysis:

Cardiovascular diseases (CVDs) comprise disorders and conditions related to circulatory system which include heart and vascular system. Drug classes used to treat cardiovascular indications such as hyperlipidaemia, hypertension are likely to fuel expansion of the global cardiovascular drug market.


Cardiovascular diseases are one of the leading causes of death worldwide. According to American Heart Association, in 2015, approximately 41.5% of the U.S. population was suffering from some form of cardiovascular disease, it is further estimated that this prevalence is likely to increase to 45% by 2035. Sedentary lifestyle, changing dietary habits and surge in associated risk factors are likely to increase the number of patients with cardiovascular diseases.

According to the Centres for Disease Control and Prevention (CDC) of the U.S., high blood pressure, high cholesterol, and smoking are key risk factors for heart disease. About half of the population of the U.S. (47%) have at least one of these three risk factors. To treat the diseases, key players are investing in to develop new drugs with better efficacy and less side effects.


Increase in number of cardiovascular disease:

As the global population pushes past 7 billion and more people reach old age, the number of deaths from cardiovascular diseases is on the rise. Cardiovascular diseases, the leading cause of premature death in the world, include heart attacks, strokes, and other circulatory diseases. Due to this, efforts to prevent and treat cardiovascular diseases through medication are on the rise resulting in slower death-rate and increased business for cardiovascular drug market.

Also there is an increase in tobacco use, unhealthy diet and obesity, physical inactivity and harmful use of alcohol resulting in more CVD and need for medication.


Stringent regulations and side-effects of cardiovascular drugs hamper the growth of global cardiovascular drugs market. Moreover, patent expiry of various blockbuster drugs also obstructs the growth of the global cardiovascular drug market. Increasing mergers and acquisitions between drug manufacturing companies and rapid product launches are key trends of the global cardiovascular drugs market.

Regional analysis:

North America dominates the global cardiovascular drugs market. This is due to increased awareness about various heart diseases in the region. The U.S. represents the largest market for cardiovascular drugs followed by Canada in North America. In Europe, Germany, the U.K., Spain, Italy and France holds major share of cardiovascular drug market. However, Asia is expected to show high growth rates in the next five years in global cardiovascular drugs market. This is due to many companies constructing their R&D facilities in the region. Less stringent wages and availability of skilled labour attracts manufacturing companies to invest in Asia. In addition, increasing awareness about heart related problems is also supporting in the growth of cardiovascular drugs market in the region. Japan, China and India are expected to be the fastest growing cardiovascular drug markets in Asia.

Key Market players:

Major players dominating the global cardiovascular disease drug market include Pfizer, Inc., AstraZeneca plc, Merck & Co., Sanofi S.A., Novartis AG, Daiichi Sankyo Company Limited, Takeda Pharmaceutical Company Limited, and Bayer AG. Other key players influencing the global cardiovascular disease drug market are Astellas Pharma Inc., Boehringer Ingelheim GmbH, United Therapeutics Corporation, Johnson & Johnson, Roche Holding AG, and Actelion Pharmaceuticals Ltd.

Key benefits of the report:

  • This study presents the analytical depiction of the global cardiovascular drug industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global cardiovascular drug market share.
  • The current market is quantitatively analyzed to highlight the global cardiovascular drug market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global cardiovascular drug market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Cardiovascular drug Market research report:

  • What are the leading market players active in the cardiovascular market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

Cardiovascular Drug Market Report Highlights

Aspects Details
By Drug Type
  • Antihypertensive
  • Antihyperlipidemic
  • Anticoagulants
  • Anti-arrhythmic
  • Others
By Disease Indication
  • Hypertension
  • Hyperlipidaemia
  • Coronary Artery Disease
  • Arrhythmia
  • Others
By Distribution Channels
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Region
  • Asia-Pacific  (CHINA, JAPAN, INDIA, SOUTH KOREA, AUSTRALIA, Rest of Asia Pacific)
  • LAMEA  (Brazil, South Africa,, Saudi Arabia, UAE, Rest of LAMEA)
Key Market Players

Novartis AG, AstraZeneca Plc, Amgen, Bayer AG, Daiichi Sankyo Company, Limited, Merck & Co., Inc., Eli Lilly & Co., Bristol-Myers Squibb Company, JOHNSON & JOHNSON (JANSSEN PHARMACEUTICALS), Pfizer Inc.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Cardiovascular Drug Market

Global Opportunity Analysis and Industry Forecast, 2023-2032